% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Maierthaler:119211,
      author       = {M. Maierthaler$^*$ and A. Benner$^*$ and M. Hoffmeister$^*$
                      and H. Surowy$^*$ and L. Jansen$^*$ and P. Knebel and J.
                      Chang$^*$ and H. Brenner$^*$ and B. Burwinkel$^*$},
      title        = {{P}lasma mi{R}-122 and mi{R}-200 family are prognostic
                      markers in colorectal cancer.},
      journal      = {International journal of cancer},
      volume       = {140},
      number       = {1},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2017-00001},
      pages        = {176 - 187},
      year         = {2017},
      abstract     = {Circulating microRNAs (miRNAs) have been proposed as
                      minimally invasive prognostic markers for various types of
                      cancers, including colorectal cancer (CRC), the third most
                      diagnosed cancer worldwide. We aimed to evaluate the levels
                      of circulating miRNAs that might serve as markers for CRC
                      prognosis and survival. We included plasma samples of 543
                      CRC patients with stage I-IV disease from a population-based
                      study carried out in Germany. After comprehensive evaluation
                      of current literature, 95 miRNAs were selected and measured
                      with Custom TaqMan® Array MicroRNA Cards. Plasma samples of
                      non-metastatic and metastatic colon cancer patients, each
                      group consisting of ten patients with 'good' and ten
                      patients with 'bad' prognosis were screened. Identified
                      candidate miRNAs were further validated by RT-qPCR in the
                      whole study cohort. The association of the miRNA levels with
                      patients' survival and the prognostic subtypes was analyzed
                      with uni- and multivariate logistic regression and Cox
                      proportional hazards regression models. Increased miR-122
                      levels were associated with a 'bad' prognostic subtype in
                      metastatic CRC (Odds ratio: 1.563, $95\%$ confidence
                      interval (CI): 1.038-2.347) and a shorter relapse-free
                      survival and overall survival for non-metastatic (Hazard
                      ratio (HR): 1.370, $95\%$ CI: 1.028-1.825; HR: 1.353, $95\%$
                      CI: 1.002-1.828) and metastatic (HR: 1.264, $95\%$ CI:
                      1.050-1.520; HR: 1.292, $95\%$ CI: 1.078-1.548) CRC
                      patients. Additionally, several members of the miR-200
                      family showed associations with patients' prognosis and
                      correlations to clinicopathological characteristics. The
                      here identified miRNA markers, miR-122 and the miR-200
                      family members, could be of use in the development of a
                      multi-marker blood test for CRC prognosis.},
      cin          = {C080 / C060 / C070 / C020 / G110 / L101},
      ddc          = {610},
      cid          = {I:(DE-He78)C080-20160331 / I:(DE-He78)C060-20160331 /
                      I:(DE-He78)C070-20160331 / I:(DE-He78)C020-20160331 /
                      I:(DE-He78)G110-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27632639},
      doi          = {10.1002/ijc.30433},
      url          = {https://inrepo02.dkfz.de/record/119211},
}